“Authors’ Reply – Comments: Serum Levels of Infliximab in Brazilian Patients With Crohn’s Disease: What Are the Reasons for Differences from Previous Studies?”. Clinics, vol. 74, Oct. 2019, p. e1517, https://doi.org/10.6061/clinics/2019/e1517.